MCID: BPL002
MIFTS: 49

Bipolar I Disorder

Categories: Mental diseases, Rare diseases

Aliases & Classifications for Bipolar I Disorder

MalaCards integrated aliases for Bipolar I Disorder:

Name: Bipolar I Disorder 12 76 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:14042
ICD9CM 35 296.50
SNOMED-CT 68 49468007

Summaries for Bipolar I Disorder

Disease Ontology : 12 A bipolar disorder that is characterized by at least one manic or mixed episode.

MalaCards based summary : Bipolar I Disorder is related to tardive dyskinesia and substance abuse. An important gene associated with Bipolar I Disorder is BDNF (Brain Derived Neurotrophic Factor), and among its related pathways/superpathways are G-Beta Gamma Signaling and Neuroscience. The drugs Dopamine and Ziprasidone have been mentioned in the context of this disorder. Affiliated tissues include brain, amygdala and cortex, and related phenotypes are behavior/neurological and muscle

Wikipedia : 76 Bipolar I disorder (BD-I; pronounced \"type one bipolar disorder\") is a bipolar spectrum disorder... more...

Related Diseases for Bipolar I Disorder

Diseases in the Bipolar Disorder family:

Bipolar Ll Disorder Bipolar I Disorder

Diseases related to Bipolar I Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 84)
# Related Disease Score Top Affiliating Genes
1 tardive dyskinesia 30.4 COMT HTR2A
2 substance abuse 30.2 BDNF COMT SLC6A4
3 schizoaffective disorder 30.0 BDNF COMT DTNBP1 HTR2A SLC6A4
4 autism spectrum disorder 29.8 BDNF HTR2A SLC6A4
5 depression 29.2 BDNF HTR1A HTR2A HTR2C SLC6A4
6 major depressive disorder 28.3 BDNF COMT HTR1A HTR2A HTR2C SLC6A4
7 anxiety 28.3 BDNF COMT HTR1A HTR2A HTR2C SLC6A4
8 autism 28.3 ANK3 BDNF COMT HTR1A HTR2A SLC6A4
9 personality disorder 28.1 BDNF COMT HTR1A HTR2A HTR2C SLC6A4
10 borderline personality disorder 27.9 BDNF COMT HTR1A HTR2A HTR2C SLC6A4
11 panic disorder 27.6 BDNF COMT HTR1A HTR2A HTR2C SLC6A4
12 mood disorder 27.5 BDNF COMT HTR1A HTR2A HTR2C PER3
13 attention deficit-hyperactivity disorder 27.5 BDNF COMT DRD1 HTR1A HTR2A HTR2C
14 obsessive-compulsive disorder 27.4 BDNF COMT DRD1 HTR1A HTR2A HTR2C
15 alcohol dependence 27.1 BDNF COMT DRD1 HTR1A HTR2A HTR2C
16 bipolar disorder 26.7 ANK3 BDNF COMT DAO DRD1 DTNBP1
17 schizophrenia 26.3 BDNF COMT DAO DRD1 DTNBP1 HTR1A
18 psychotic disorder 25.0 BDNF COMT DAO DRD1 DTNBP1 HTR1A
19 alzheimer disease 5 10.6 HTR2A SLC6A4
20 alcoholic psychosis 10.6 HTR2A SLC6A4
21 schizophreniform disorder 10.5 COMT NRG1
22 oppositional defiant disorder 10.5 COMT SLC6A4
23 dysthymic disorder 10.5 HTR2A SLC6A4
24 social phobia 10.5 HTR1A SLC6A4
25 kleptomania 10.5 HTR1A SLC6A4
26 schizoid personality disorder 10.5 HTR1A HTR2A
27 hypoactive sexual desire disorder 10.5 HTR1A HTR2A
28 specific developmental disorder 10.5 BDNF COMT SLC6A4
29 substance-induced psychosis 10.5 HTR1A HTR2A
30 cannabis dependence 10.5 COMT NRG1
31 bruxism 10.4 HTR2A SLC6A4
32 fibromyalgia 10.4 COMT HTR2A SLC6A4
33 phobic disorder 10.4 COMT HTR1A SLC6A4
34 alexithymia 10.4 COMT HTR1A SLC6A4
35 drug-induced mental disorder 10.3 HTR1A HTR2A
36 brunner syndrome 10.3 COMT HTR1A SLC6A4
37 drug psychosis 10.3 HTR1A HTR2A
38 chronic fatigue syndrome 10.3 COMT HTR1A SLC6A4
39 intermittent explosive disorder 10.3 HTR1A SLC6A4
40 aging 10.3
41 pathological gambling 10.3 DRD1 HTR2A SLC6A4
42 traumatic brain injury 10.3 BDNF COMT
43 agoraphobia 10.3 HTR1A SLC6A4
44 serotonin syndrome 10.2 HTR1A HTR2A SLC6A4
45 paranoid schizophrenia 10.2 BDNF COMT HTR2A SLC6A4
46 bulimia nervosa 10.1 BDNF COMT HTR2A SLC6A4
47 post-traumatic stress disorder 10.1 BDNF COMT HTR2A SLC6A4
48 postpartum depression 10.1 BDNF COMT HTR1A SLC6A4
49 anorexia nervosa 10.1 BDNF COMT HTR2A SLC6A4
50 generalized anxiety disorder 10.0 BDNF HTR1A HTR2A SLC6A4

Graphical network of the top 20 diseases related to Bipolar I Disorder:



Diseases related to Bipolar I Disorder

Symptoms & Phenotypes for Bipolar I Disorder

MGI Mouse Phenotypes related to Bipolar I Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.97 SLC6A4 ANK3 BDNF COMT DAO DRD1
2 muscle MP:0005369 9.43 SLC6A4 DRD1 DTNBP1 EGR3 HTR2A HTR2C
3 nervous system MP:0003631 9.4 SLC6A4 ANK3 BDNF COMT DAO DRD1

Drugs & Therapeutics for Bipolar I Disorder

Drugs for Bipolar I Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 143)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
2
Ziprasidone Approved Phase 4,Phase 3,Phase 2 146939-27-7 60854
3
Carbamazepine Approved, Investigational Phase 4,Phase 3,Phase 1 298-46-4 2554
4
Olanzapine Approved, Investigational Phase 4,Phase 3 132539-06-1 4585
5
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 99-66-1 3121
6
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 129722-12-9 60795
7
Oxcarbazepine Approved Phase 4 28721-07-5 34312
8
Coal tar Approved Phase 4 8007-45-2
9
Infliximab Approved Phase 4 170277-31-3
10
Cocaine Approved, Illicit Phase 4 50-36-2 5760 446220
11
Risperidone Approved, Investigational Phase 4,Phase 3 106266-06-2 5073
12
Lamotrigine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 84057-84-1 3878
13
Benzocaine Approved, Investigational Phase 4,Not Applicable 1994-09-7, 94-09-7 2337
14
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
15
Choline Approved, Nutraceutical Phase 4 62-49-7 305
16 tannic acid Approved, Nutraceutical Phase 4,Not Applicable
17 Quetiapine Fumarate Phase 4,Phase 3,Phase 2,Not Applicable 111974-72-2
18 Lithium carbonate Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 554-13-2
19 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
20 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
21 GABA Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
22 Serotonin Agents Phase 4,Phase 3,Phase 2,Phase 1
23 Serotonin Antagonists Phase 4,Phase 3,Phase 2,Phase 1
24 Serotonin Uptake Inhibitors Phase 4,Phase 3
25 Gastrointestinal Agents Phase 4,Phase 3
26 Sodium Channel Blockers Phase 4,Phase 3,Phase 2,Phase 1
27 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
28 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 1
29 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3
30 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 3,Phase 2,Phase 1
31 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Diuretics, Potassium Sparing Phase 4,Phase 3,Phase 2,Phase 1
33 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Dopamine Antagonists Phase 4,Phase 3,Phase 2,Phase 1
35 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Excitatory Amino Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Excitatory Amino Acids Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
38 Anticonvulsants Phase 4,Phase 3,Phase 2,Phase 1
39 Antidepressive Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
40 Antiemetics Phase 4,Phase 3
41 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Antimanic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Autonomic Agents Phase 4,Phase 3
45 calcium channel blockers Phase 4,Phase 3,Phase 2,Phase 1
46 Cytidine Diphosphate Choline Phase 4
47 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 3
48 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3
49 Anesthetics Phase 4,Phase 2,Phase 1,Early Phase 1
50 Nootropic Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 208)
# Name Status NCT ID Phase Drugs
1 Potentiation of Quetiapine Treatment With Lithium or Aripiprazole in Bipolar 1 Nonresponders Patients Unknown status NCT01710163 Phase 4 Lithium;Aripiprazole
2 Comparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania Unknown status NCT01893229 Phase 4 Lithium;Valproate;Oxcarbazepine;Quetiapine;Olanzapine;Ziprasidone
3 Efficacy and Safety of Utapine vs. Seroquel in Patients With Bipolar Mania Unknown status NCT01043679 Phase 4 Utapine;Seroquel
4 Olanzapine Versus Active Comparator in the Treatment of Bipolar I Disorder Completed NCT00034580 Phase 4 olanzapine;risperidone
5 A Phase IV Study of the Safety and Efficacy of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With A Recent Manic or Mixed Episode Completed NCT00277212 Phase 4 Lamotrigine + Aripiprazole;Lamotrigine + Placebo
6 A Comparison of Olanzapine in Combination With a Mood Stabilizer vs Mood Stabilizer Alone, in Mixed Bipolar Patients Completed NCT00402324 Phase 4 olanzapine;placebo;divalproex
7 The Young Adult and Pediatric Bipolar Study Completed NCT00350857 Phase 4 Extended-Release Carbamazepine
8 The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder Completed NCT00044187 Phase 4 Sibutramine
9 Study in Adolescents With Schizophrenia or Bipolar Disorder Completed NCT00982020 Phase 4 Olanzapine
10 Olanzapine Versus Placebo in the Treatment of Mania in Adolescents With Bipolar I Disorder Completed NCT00050206 Phase 4 Olanzapine;Placebo
11 Effects of Comorbid Personality Disorder on the Treatment of Bipolar I Disorder Completed NCT00178061 Phase 4
12 Olanzapine vs. Comparator and Placebo in the Treatment of Patients With Bipolar I Disorder Completed NCT00094549 Phase 4 olanzapine;divalproex sodium;placebo
13 Citicoline for Bipolar 1 Disorder and Cocaine Dependence Completed NCT00619723 Phase 4 Citicoline;Placebo
14 Efficacy of Combined Treatment for Young Bipolar I Disorder Completed NCT00976794 Phase 4 lithium plus carbamazepine;lithium plus valproate
15 Olanzapine Plus Carbamazepine in the Treatment of Bipolar I Mania Completed NCT00190892 Phase 4 olanzapine;carbamazepine
16 Open Label Extension Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder Completed NCT00139594 Phase 4 licarbazepine
17 A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania Completed NCT00261443 Phase 4 Lithium or Valproate with placebo (PBO);Lithium or Valproate with Aripiprazole
18 A Study for Assessing Treatment of Patients Ages 10-17 With Bipolar Depression Completed NCT00844857 Phase 4 Olanzapine Fluoxetine Combination (OFC);Placebo
19 Sequential Multiple Assignment Treatment for Bipolar Disorder Completed NCT01588457 Phase 4 Lithium/Lithium Carbonate;Divalproex;Lamotrigine;Quetiapine
20 ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness Completed NCT00484471 Phase 4 aripiprazole;valproate;placebo
21 Quetiapine Fumarate (Seroquel) as Mono-Therapy or Adjunct to Lithium in the Treatment of Patients With Acute Mania in Bipolar Disorder Completed NCT00672490 Phase 4 Quetiapine Fumarate;Lithium
22 A Study of Infliximab for Treatment Resistant Major Depression Completed NCT00463580 Phase 4 infliximab (remicade);Placebo
23 DB/Maintenance of Equetro (Carbamazepine) in Children With Acute Manic or Mixed Bipolar 1 Disorder Recruiting NCT02623504 Phase 4 Carbamazepine;Placebo
24 Neurofunctional and Neurochemical Markers of Treatment Response in Bipolar Disorder Active, not recruiting NCT00608075 Phase 4 lithium;Lithium
25 Seroquel in Acute Mania: Study to Investigate if Valproate Add-On Therapy is Superior to Quetiapine Monotherapy in Acutely Manic Patients Terminated NCT00139074 Phase 4 Quetiapine fumarate;sodium valproate
26 Study of the Efficacy of Adjunctive Lithium Treatment for the Treatment of Psychotic Mania Withdrawn NCT01495156 Phase 4 Lithium treatment in combination with a SGA (Second Generation Antipsychotic);Placebo/Adjunctive SGA treatment
27 Safety and Efficacy Study of Lithium in Bipolar Disorder Unknown status NCT00422331 Phase 3 Lithium Carbonate Capsule
28 Lithium Versus Divalproex for Treating Pediatric Bipolar Disorder Unknown status NCT00221429 Phase 3 lithium sodium divalproex
29 Long-term Safety and Tolerability of Cariprazine for Bipolar I Disorder Completed NCT01059539 Phase 3 cariprazine
30 A Study for the Treatment of Mania Associated With Bipolar I Disorder in Children and Adolescents Completed NCT00195780 Phase 3 Divalproex Sodium (Depakote ER)
31 Safety and Efficacy of Cariprazine for Bipolar I Disorder Completed NCT01058668 Phase 3 Cariprazine;Placebo
32 A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder Completed NCT00490971 Phase 3 Olanzapine;Paliperidone ER;Placebo
33 Efficacy & Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder Completed NCT00107731 Phase 3 quetiapine fumarate;lithium;divalproex
34 Quetiapine Fumarate (SEROQUEL) in the Treatment of Adolescent Patients With Schizophrenia and Bipolar I Disorder Completed NCT00227305 Phase 3 quetiapine fumarate
35 This is an Open-label, Multi-center, Extension Study Designed to Evaluate the Longer Term Safety, Tolerability and Effectiveness of Lurasidone, Flexibly Dosed, Adjunctive to Lithium or Divalproex for the Treatment of Subjects With Bipolar I Disorder Who H Completed NCT01575561 Phase 3 Lurasidone
36 An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750-2000 mg/d in the Treatment of Manic Episodes of Bipolar I Disorder Completed NCT00238485 Phase 3 Licarbazepine
37 Safety and Efficacy of Olanzapine in the Long-term Treatment for Bipolar I Disorder, Depressed Completed NCT00618748 Phase 3 Olanzapine
38 Lurasidone and Cognition in Bipolar I Disorder Completed NCT02147379 Phase 3 Lurasidone
39 Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder Completed NCT01305408 Phase 3 Armodafinil;Placebo
40 Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder Completed NCT01121536 Phase 3 Armodafinil
41 Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder Completed NCT01072630 Phase 3 Armodafinil;Placebo
42 A Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder Completed NCT01072929 Phase 3 Armodafinil;Placebo
43 Trial of Olanzapine in Patients With Manic or Mixed Episode of Bipolar I Disorder Completed NCT00129220 Phase 3 olanzapine;haloperidol;placebo
44 Safety and Tolerability of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed) Completed NCT00265330 Phase 3 Ziprasidone oral capsules
45 An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder. Completed NCT00228059 Phase 3 Licarbazepine
46 Aripiprazole in Children and Adolescents With Bipolar I Disorder Completed NCT00110461 Phase 3 Aripiprazole;Aripiprazole;placebo
47 A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode Completed NCT00094432 Phase 3 Aripiprazole;Placebo
48 An Evaluation Of BW430C (Lamotrigine) Versus Placebo In The Prevention Of Mood Episodes In Bipolar I Disorder Patients Completed NCT00550407 Phase 3 lamotrigine;Placebo
49 Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Alcohol Dependency in Patients With Bipolar Disorder Completed NCT00114686 Phase 3 Quetiapine fumarate;lithium;divalproex
50 Efficacy and Safety of Olanzapine in the Extended Treatment for Manic or Mixed Episode of Bipolar I Disorder Completed NCT00266630 Phase 3 olanzapine;lithium;valproate;carbamazepine

Search NIH Clinical Center for Bipolar I Disorder

Genetic Tests for Bipolar I Disorder

Anatomical Context for Bipolar I Disorder

MalaCards organs/tissues related to Bipolar I Disorder:

41
Brain, Amygdala, Cortex, Testes, Bone, Eye, Thyroid

Publications for Bipolar I Disorder

Articles related to Bipolar I Disorder:

(show top 50) (show all 680)
# Title Authors Year
1
The association between mood state and chronobiological characteristics in bipolar I disorder: a naturalistic, variable cluster analysis-based study. ( 29457195 )
2018
2
Can Residual Symptoms During Inter-Episode Period after Partial Remission in Bipolar I Disorder Have Cyclic Patterns with Specific Frequencies? ( 29486550 )
2018
3
Lack of emotional gaze preferences using eye-tracking in remitted bipolar I disorder. ( 29968068 )
2018
4
Budget impact analysis of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA. ( 29694243 )
2018
5
Quetiapine Related Acute Paralytic Ileus in a Bipolar I Disorder Patient with Successful Low Dose Amisulpride Substitution: A Case Report. ( 29739140 )
2018
6
The effects of psychoeducational family intervention on coping strategies of relatives of patients with bipolar I disorder: results from a controlled, real-world, multicentric study. ( 29692615 )
2018
7
Cognitive functioning in first episode bipolar I disorder patients with and without history of psychosis. ( 29055258 )
2018
8
Anterior Cingulate Cortex Glutamatergic Metabolites and Mood Stabilizers in Euthymic Bipolar I Disorder Patients: A Proton Magnetic Resonance Spectroscopy Study. ( 29789269 )
2018
9
Psychosocial functioning in patients with psychotic and non-psychotic bipolar I disorder. A comparative study with individuals with schizophrenia. ( 29316520 )
2018
10
Cardiometabolic risks and omega-3 index in recent-onset bipolar I disorder. ( 29479787 )
2018
11
Influence of age at onset on the course and outcome of bipolar I disorder: Findings from a retrospective study. ( 29494947 )
2018
12
Spotlight on once-monthly long-acting injectable aripiprazole and its potential as maintenance treatment for bipolar I disorder in adult patients. ( 29391801 )
2018
13
An overview of pharmacotherapy for bipolar I disorder. ( 29361880 )
2018
14
The association between social skills deficits and family history of mood disorder in bipolar I disorder. ( 29590265 )
2018
15
Cost-effectiveness of long-acting injectable aripiprazole once-monthly 400A mg in bipolar I disorder in the USA. ( 29694244 )
2018
16
Could schizoaffective disorder, schizophrenia and bipolar I disorder be distinguishable using cognitive profiles? ( 29852325 )
2018
17
No neuronal autoantibodies detected in plasma of patients with a bipolar I disorder. ( 29136601 )
2018
18
Perception of inpatients following remission of a manic episode in bipolar I disorder on a group-based Psychoeducation program: a qualitative study. ( 29378562 )
2018
19
Predictors and outcomes of somatization in bipolar I disorder: A latent class mixture modeling approach. ( 29174742 )
2018
20
Comparison of salivary testosterone levels in different phases of bipolar I disorder and control group. ( 29887899 )
2018
21
Mixed Features in Bipolar I Disorder and the Effect of Lithium on Suicide. ( 29301424 )
2018
22
Psychoeducation for psychiatric inpatients following remission of a manic episode in bipolar I disorder: A randomized controlled trial. ( 29578271 )
2018
23
Association of intracortical myelin and cognitive function in bipolar I disorder. ( 29536533 )
2018
24
Symptoms and functioning with aripiprazole once-monthly injection as maintenance treatment for bipolar I disorder. ( 29174738 )
2018
25
Aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a 52-week, multicenter, open-label study. ( 29886522 )
2018
26
Secular trends in the age at onset of bipolar I disorder - Support for birth cohort effects from interational, multi-centre clinical observational studies. ( 29734127 )
2018
27
Quality of life in stabilized outpatients with bipolar I disorder: Associations with resilience, internalized stigma, and residual symptoms. ( 29909303 )
2018
28
Aripiprazole Long-Acting Injectable for Maintenance Treatment of Bipolar I Disorder in Adults. ( 29341822 )
2018
29
Double trouble: weekend sleep changes are associated with increased impulsivity among adolescents with bipolar I disorder. ( 29781205 )
2018
30
Assessment of cognitive functions in bipolar I disorder: A 1-year naturalistic follow-up study. ( 29314557 )
2018
31
Transitioning from Bipolar II to Bipolar I Disorder in Late Life: Implications for Practice. ( 29725185 )
2018
32
Glycogen synthase kinase-3I^ activity and cognitive functioning in patients with bipolar I disorder. ( 29433844 )
2018
33
Increased cooperative behavior across remitted bipolar I disorder and major depression: Insights utilizing a behavioral economic trust game. ( 27868424 )
2017
34
Olfactory Neuroepithelial Neural Progenitor Cells from Subjects with Bipolar I Disorder. ( 28469524 )
2017
35
Preventive Effects of Lamotrigine in Bipolar II Versus Bipolar I Disorder. ( 28817765 )
2017
36
Efficacy and safety of sublingual ramelteon as an adjunctive therapy in the maintenance treatment of bipolar I disorder in adults: A phase 3, randomized controlled trial. ( 28662460 )
2017
37
Neurocognition in patients with psychotic and non-psychotic bipolar I disorder. A comparative study with individuals with schizophrenia. ( 28709024 )
2017
38
Response to inhaled loxapine in patients with schizophrenia or bipolar I disorder: PANSS-EC responder analyses. ( 29163985 )
2017
39
Joint analysis of cognitive and circadian variation in Schizophrenia and Bipolar I Disorder. ( 29158147 )
2017
40
Neurocognitive function in clinically stable individuals with long-term bipolar I disorder: Comparisons with schizophrenia patients and controls. ( 28433073 )
2017
41
Neurocognitive functioning, clinical course and functional outcome in first-treatment bipolar I disorder patients with and without clinical relapse: A 1-year follow-up study. ( 29121444 )
2017
42
Epidemiology of DSM-5 bipolar I disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions - III. ( 27814503 )
2017
43
Effectiveness of the Dader Method for Pharmaceutical Care on Patients with Bipolar I Disorder: Results from the EMDADER-TAB Study. ( 28025928 )
2017
44
Autistic and schizotypal traits and global functioning in bipolar I disorder. ( 27736738 )
2017
45
Randomized, Double-Blind, Placebo-Controlled Trial of Asenapine Maintenance Therapy in Adults With an Acute Manic or Mixed Episode Associated With Bipolar I Disorder. ( 28946761 )
2017
46
Effects of asenapine on agitation and hostility in adults with acute manic or mixed episodes associated with bipolar I disorder. ( 29270013 )
2017
47
Comparison of metabolic syndrome prevalence in patients with schizophrenia and bipolar I disorder. ( 28927969 )
2017
48
Initial symptom severity of bipolar I disorder and the efficacy of olanzapine: a meta-analysis of individual participant data from five placebo-controlled studies. ( 28939419 )
2017
49
Asenapine Treatment in Pediatric Patients with Bipolar I Disorder or Schizophrenia: A Review. ( 29170943 )
2017
50
Plasma interleukin-6 in remitted early bipolar I disorder and subjects at high-risk for bipolar disorder. ( 28365164 )
2017

Variations for Bipolar I Disorder

Expression for Bipolar I Disorder

Search GEO for disease gene expression data for Bipolar I Disorder.

Pathways for Bipolar I Disorder

Pathways related to Bipolar I Disorder according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.7 BDNF DRD1 HTR2A HTR2C TUBA8
2 12.24 COMT DTNBP1 EGR3 HTR1A
4
Show member pathways
11.94 DRD1 HTR2A HTR2C
5 11.83 BDNF HTR1A HTR2A SLC6A4
6
Show member pathways
11.62 DRD1 HTR1A HTR2A HTR2C
7 11.51 HTR1A HTR2A HTR2C SLC6A4
8 11.2 DRD1 HTR2A HTR2C TUBA8
9
Show member pathways
10.89 COMT SLC6A4
10 10.76 HTR2A HTR2C
11 10.37 HTR1A HTR2A HTR2C SLC6A4

GO Terms for Bipolar I Disorder

Cellular components related to Bipolar I Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.96 ANK3 COMT DRD1 DTNBP1 GRID1 HTR1A
2 integral component of plasma membrane GO:0005887 9.8 DRD1 HTR1A HTR2A HTR2C NRG1 SLC6A4
3 postsynaptic membrane GO:0045211 9.46 ANK3 COMT DTNBP1 GRID1
4 axon GO:0030424 9.43 ANK3 BDNF COMT DTNBP1 HTR2A NRG1
5 dendrite GO:0030425 9.17 ANK3 BDNF COMT HTR1A HTR2A HTR2C

Biological processes related to Bipolar I Disorder according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.85 ANK3 DRD1 DTNBP1 NRG1 SLC6A4
2 response to drug GO:0042493 9.83 COMT DRD1 HTR2A HTR2C SLC6A4
3 locomotory behavior GO:0007626 9.73 DRD1 HTR2C NRG1
4 circadian rhythm GO:0007623 9.72 EGR3 PER3 SLC6A4
5 synapse assembly GO:0007416 9.69 BDNF DRD1 NRG1
6 neuronal action potential GO:0019228 9.61 ANK3 DRD1
7 G-protein coupled serotonin receptor signaling pathway GO:0098664 9.61 HTR1A HTR2A
8 behavioral response to cocaine GO:0048148 9.6 DRD1 HTR2A
9 regulation of dopamine secretion GO:0014059 9.59 DTNBP1 HTR2A
10 temperature homeostasis GO:0001659 9.58 DRD1 HTR2A
11 vasoconstriction GO:0042310 9.58 HTR1A SLC6A4
12 behavioral fear response GO:0001662 9.58 DRD1 HTR1A HTR2C
13 dopamine metabolic process GO:0042417 9.57 COMT DRD1
14 memory GO:0007613 9.56 BDNF DRD1 HTR2A SLC6A4
15 regulation of behavior GO:0050795 9.54 HTR1A HTR2A
16 regulation of dopamine metabolic process GO:0042053 9.52 DRD1 HTR1A
17 peripheral nervous system development GO:0007422 9.5 BDNF EGR3 NRG1
18 regulation of hormone secretion GO:0046883 9.49 HTR1A HTR2A
19 positive regulation of phosphatidylinositol biosynthetic process GO:0010513 9.48 HTR2A HTR2C
20 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.46 DRD1 HTR1A HTR2A HTR2C
21 phospholipase C-activating serotonin receptor signaling pathway GO:0007208 9.37 HTR2A HTR2C
22 behavior GO:0007610 9.13 HTR1A HTR2A HTR2C
23 serotonin receptor signaling pathway GO:0007210 8.8 HTR1A HTR2A HTR2C

Molecular functions related to Bipolar I Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 obsolete signal transducer activity GO:0004871 9.62 DRD1 HTR1A HTR2A HTR2C
2 G-protein alpha-subunit binding GO:0001965 9.37 DRD1 HTR2A
3 neurotransmitter receptor activity GO:0030594 9.33 HTR1A HTR2A HTR2C
4 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding GO:0071886 9.26 HTR2A HTR2C
5 G-protein coupled serotonin receptor activity GO:0004993 9.13 HTR1A HTR2A HTR2C
6 serotonin binding GO:0051378 8.8 HTR1A HTR2A HTR2C

Sources for Bipolar I Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....